Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 4/2014

01-12-2014 | Translational Colorectal Oncology (Y Jiang, Section Editor)

The Role of Predictive Molecular Biomarkers for the Treatment of Metastatic Colorectal Cancer

Authors: James J. Lee, Edward Chu

Published in: Current Colorectal Cancer Reports | Issue 4/2014

Login to get access

Abstract

Colorectal cancer (CRC) is a major public health problem in the USA and globally. Over the past 20 years, significant advances have been made in the treatment of patients with metastatic colorectal cancer (mCRC). Recent efforts have focused on developing molecular biomarkers to further define the subset of patients with mCRC who would derive a substantial benefit from anti-epidermal growth factor receptor (EGFR) therapy. Activating mutations in KRAS and NRAS are a predictive marker for resistance to anti-EGFR therapy in mCRC. BRAF V600E and PIK3CA mutations have been reported as negative predictive markers for anti-EGFR therapy in mCRC. Microsatellite instability and immunologic biomarkers may be predictive markers for immunotherapy, including immune-checkpoint inhibitors in the near future. Next-generation sequencing technology is a powerful new tool for the discovery of predictive molecular biomarkers and to facilitate the delivery of personalized medicine. Herein, we review the current status of predictive molecular biomarker research in the treatment of mCRC.
Literature
1.
2.
Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–34.PubMedCrossRef
3.
Douillard J-Y, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697–705.PubMedCrossRef
4.
Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:4706–13.PubMedCrossRef
5.
Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.PubMedCrossRef
6.
Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011;22:1535–46.PubMedCrossRef
7.
Peeters M, Oliner KS, Parker A, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res. 2013;19:1902–12.PubMedCrossRef
8.
De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304:1812–20.PubMedCrossRef
9.
Peeters M, Douillard JY, Van Cutsem E, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol. 2013;31:759–65.PubMedCrossRef
10.
Andre T, Blons H, Mabro M, et al. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol. 2013;24:412–9.PubMedCrossRef
11.
Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009;101:715–21.PubMedCrossRefPubMedCentral
12.•
De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753–62. This large retrospective analysis showed that the presence of BRAF mutations is associated with poor response to anti-EGFR therapy in mCRC.PubMedCrossRef
13.
14.
15.••
Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023–34. The authors showed that patients with tumors expressing any activating RAS mutations do not benefit from the addition of panitumumab.PubMedCrossRef
16.
Heinemann V, Fischer von Weikersthal L, Decker T, et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). ASCO Meeting Abstracts 31:LBA3506, 2013.
17.••
Stintzing S, Jung A, Rossius L, et al. Mutations within the EGFR signaling pathway: influence on efficacy in FIRE-3—a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. ASCO Meeting Abstracts 32:445, 2014. The authors showed that patients with tumors expressing any activating RAS mutations do not benefit from the addition of cetuximab.
18.••
Bokemeyer C, Kohne C-H, Ciardiello F, et al. Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. ASCO Meeting Abstracts 32:3505, 2014. The authors showed that patients with tumors expressing any activating RAS mutations do not benefit from the addition of cetuximab.
19.
DiNicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705–12.CrossRef
20.
Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011–9.PubMedCrossRef
21.
Seymour MT, Brown SR, Middleton G, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 2013;14:749–59.PubMedCrossRefPubMedCentral
22.
Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009;69:1851–7.PubMedCrossRef
23.
Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol. 2009;27:2622–9.PubMedCrossRef
24.
Tol J, Dijkstra JR, Klomp M, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer. 2010;46:1997–2009.PubMedCrossRef
25.
Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009;27:5924–30.PubMedCrossRef
26.
Ulivi P, Capelli L, Valgiusti M, et al. Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. J Transl Med. 2012;10:87.PubMedCrossRefPubMedCentral
27.
Prenen H, De Schutter J, Jacobs B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res. 2009;15:3184–8.PubMedCrossRef
28.
Karapetis CS, Jonker D, Daneshmand M, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer—results from NCIC CTG/AGITG CO.17. Clin Cancer Res. 2014;20:744–53.PubMedCrossRef
29.
Sridharan M, Hubbard JM, Grothey A. Colorectal cancer: how emerging molecular understanding affects treatment decisions. Oncology (Williston Park). 2014;28:110–8.
30.
31.••
Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–7, 2012. The authors reported detailed genomic profiling of colorectal cancer.
32.
Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26:5783–8.PubMedCrossRefPubMedCentral
33.
Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011;103:863–75.PubMedCrossRefPubMedCentral
34.
Alexander J, Watanabe T, Wu TT, et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158:527–35.PubMedCrossRefPubMedCentral
35.
36.
Ogino S, Nosho K, Irahara N, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009;15:6412–20.PubMedCrossRefPubMedCentral
37.
Ling A, Edin S, Wikberg ML, et al. The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues. Br J Cancer. 2014;110:2551–9.PubMedCrossRef
38.
Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.PubMedCrossRef
39.
Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66.PubMedCrossRef
40.
Galon J, Pages F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 10, 2012.
41.••
Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532–6. The authors reported that ctDNA may play a critical roel in the development of molecular biomarkers by showing the detection of KRAS mutations in ctDNA several months prior to radiographic evidence of disease progression in mCRC patients treated with anti-EGFR therapy.PubMedPubMedCentral
42.••
Diaz Jr LA, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537–40. The authors reported that ctDNA may play a critical role in the development of molecular biomarkers by showing the detection of KRAS mutations in ctDNA several months prior to radiographic evidence of disease progression in mCRC patients treated with anti-EGFR therapy.PubMedPubMedCentral
43.
Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:548–54.PubMedCrossRef
44.
Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 2012;4:162ra154.PubMedCrossRefPubMedCentral
45.
46.
Lambrechts D, Lenz HJ, de Haas S, et al. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol. 2013;31:1219–30.PubMedCrossRef
47.
Custodio A, Barriuso J, de Castro J, et al. Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives. Cancer Treat Rev. 2013;39:908–24.PubMedCrossRef
48.
Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012;30:2119–27.PubMedCrossRef
49.
Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28:453–9.PubMedCrossRefPubMedCentral
50.
Raffan E, Semple RK. Next-generation sequencing—implications for clinical practice. Br Med Bull. 2011;99:53–71.PubMedCrossRef
51.
Johansen Taber KA, Dickinson BD, Wilson M. The promise and challenges of next-generation genome sequencing for clinical care. JAMA Intern Med. 2014;174:275–80.PubMedCrossRef
52.
53.
54.
Metadata
Title
The Role of Predictive Molecular Biomarkers for the Treatment of Metastatic Colorectal Cancer
Authors
James J. Lee
Edward Chu
Publication date
01-12-2014
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 4/2014
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-014-0246-1

Other articles of this Issue 4/2014

Current Colorectal Cancer Reports 4/2014 Go to the issue

Immunotherapy of Malignancy (R Kim, Section Editor)

Peptide Vaccines for Treatment of Colon Cancer: Have We Made Progress?

Molecular Biology (S Anant, Section Editor)

Targeting Cancer Stem Cells by Phytochemicals: a Multimodal Approach to Colorectal Cancer

Molecular Biology (S Anant, Section Editor)

Histone Demethylases in Colon Cancer

Immunotherapy of Malignancy (R Kim, Section Editor)

Dendritic Cell Cancer Vaccines for Treatment of Colon Cancer

Molecular Biology (S Anant, Section Editor)

Role of Prolactin and Its Receptor in Colorectal Cancer

Molecular Biology (S Anant, Section Editor)

Mechanisms by Which Pleiotropic Amphiphilic n−3 PUFA Reduce Colon Cancer Risk
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits